Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection

Journal of Viral Hepatitis

Volumn 15, Issue 3, 2008, Pages 200-211

  Ciesek, S ^a   Liermann, H ^a   Hadem, J ^a   Greten, T ^a   Tillmann, H L ^a   Cornberg, M ^a   Aslan, N ^a   Manns, M P ^a   Wedemeyer, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

CD1c positive dendritic cells; Hepatitis C; TRAIL

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CD1C ANTIGEN; PEGINTERFERON ALPHA2B; RIBAVIRIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ALLOIMMUNITY; ANTIVIRAL THERAPY; ARTICLE; AUTOIMMUNITY; BLOOD; BONE MARROW CELL; CELL KILLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DENDRITIC CELL; ENDOCYTOSIS; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MEASLES VIRUS; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TARGET CELL; VIRUS IMMUNITY;

ADULT; ANTIGENS, CD1; ANTIGENS, SURFACE; APOPTOSIS; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; GLYCOPROTEINS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 38449118450     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00930.x     Document Type: Article

References (56)

1. Zinkernagel RM. Immunology taught by viruses. Science 1996 271 (5246 173 178.
2. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001 19 : 65 91.
3. Welsh RM, McNally JM. Immune deficiency, immune silencing, and clonal exhaustion of T cell responses during viral infections. Curr Opin Microbiol 1999 2 (4 382 387.
4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998 392 (6673 245 252.
5. Steinman RM, Inaba K. Myeloid dendritic cells. J Leuk Biol 1999 66 (2 205 208.
6. Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001 2 (7 585 589.
7. Fanger NA, Maliszewski CR, Schooley K, Griffith TS. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 1999 190 (8 1155 1164.
8. Wiley SR, Schooley K, Smolak PJ et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995 3 (6 673 682.
9. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998 10 (5 559 563.
10. Walczak H, Miller RE, Ariail K et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999 5 (2 157 163.
11. Vidalain PO, Azocar O, Lamouille B, Astier A, Rabourdin-Combe C, Servet-Delprat C. Measles virus induces functional TRAIL production by human dendritic cells. J Virol 2000 74 (1 556 559.
12. Raftery MJ, Schwab M, Eibert SM, Samstag Y, Walczak H, Schonrich G. Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity 2001 15 (6 997 1009.
13. Strater J, Walczak H, Pukrop T et al. TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections. Gastroenterology 2002 122 (3 659 666.
14. Clarke P, Meintzer SM, Gibson S et al. Reovirus-induced apoptosis is mediated by TRAIL. J Virol 2000 74 (17 8135 8139.
15. Mundt B, Kuhnel F, Zender L et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 2003 17 (1 94 96.
16. Beaulieu S, Lafontaine M, Richer M, Courchesne I, Cohen EA, Bergeron D. Characterization of the cytotoxic factor(s) released from thymic dendritic cells upon human immunodeficiency virus type 1 infection. Virology 1998 241 (2 285 297.
17. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000 132 (4 296 305.
18. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005 5 (3 215 229.
19. Corado J, Toro F, Rivera H, Bianco NE, Deibis L, De Sanctis JB. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol 1997 109 (3 451 457.
20. Crotta S, Stilla A, Wack A et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002 195 (1 35 41.
21. Abe M, Kajino K, Akbar SM, Yamamura K, Onji M, Hino O. Loss of immunogenecity of liver dendritic cells from mouse with chronic hepatitis. Int J Mol Med 2002 9 (1 71 76.
22. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001 120 (2 512 524.
23. Kanto T, Hayashi N, Takehara T et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 1999 162 (9 5584 5591.
24. Longman RS, Talal AH, Jacobson IM, Albert ML, Rice CM. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood 2004 103 (3 1026 1029.
25. Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis 2005 192 (3 497 503.
26. Dzionek A, Fuchs A, Schmidt P et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000 165 (11 6037 6046.
27. Krug A, Towarowski A, Britsch S et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001 31 (10 3026 3037.
28. Penna G, Vulcano M, Sozzani S, Adorini L. Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells. Hum Immunol 2002 63 (12 1164 1171.
29. Wedemeyer H, Pethig K, Wagner D et al. Long-term outcome of chronic hepatitis B in heart transplant recipients. Transplantation 1998 66 (10 1347 1353.
30. Fujimoto M, Poe JC, Inaoki M, Tedder TF. CD19 regulates B lymphocyte responses to transmembrane signals. Semin Immunol 1998 10 (4 267 277.
31. Dzionek A, Inagaki Y, Okawa K et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions(1). Hum Immunol 2002 63 (12 1133 1148.
32. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999 189 (9 1451 1460.
33. Sato K, Hida S, Takayanagi H et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 2001 31 (11 3138 3146.
34. Josien R, Heslan M, Soulillou JP, Cuturi MC. Rat spleen dendritic cells express natural killer cell receptor protein 1 (NKR-P1) and have cytotoxic activity to select targets via a Ca2+-dependent mechanism. J Exp Med 1997 186 (3 467 472.
35. Suss G, Shortman K. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med 1996 183 (4 1789 1796.
36. Clark FJ, Freeman L, Dzionek A et al. Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease. Transplantation 2003 75 (2 221 225.
37. Fugier-Vivier I, Servet-Delprat C, Rivailler P, Rissoan MC, Liu YJ, Rabourdin-Combe C. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. J Exp Med 1997 186 (6 813 823.
38. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998 392 (6671 86 89.
39. Mellor J, Haydon G, Blair C, Livingstone W, Simmonds P. Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells. J Gen Virol 1998 4 : 705 714.
40. Wedemeyer H, He XS, Nascimbeni M et al. Impaired effector function of hepatitis C virus-specific CD8(+) T cells in chronic hepatitis C virus infection. J Immunol 2002 169 (6 3447 3458.
41. Gruener NH, Lechner F, Jung MC et al. Sustained dysfunction of antiviral CD8(+) T lymphocytes after infection with hepatitis C virus. J Virol 2001 75 (12 5550 5558.
42. Pileri P, Uematsu Y, Campagnoli S et al. Binding of hepatitis C virus to CD81. Science 1998 282 (5390 938 941.
43. Petracca R, Falugi F, Galli G et al. Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol 2000 74 (10 4824 4830.
44. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002 195 (1 43 49.
45. Wack A, Soldaini E, Tseng C, Nuti S, Klimpel G, Abrignani S. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol 2001 31 (1 166 175.
46. Nattermann J, Zimmermann H, Iwan A et al. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C. Hepatology 2006 44 (4 945 954.
47. Biron CA. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol 1998 10 (5 383 390.
48. Wedemeyer H, Wiegand J, Cornberg M, Manns MP. Polyethylene glycol-interferon: current status in hepatitis C virus therapy. J Gastroenterol Hepatol 2002 17 (Suppl. 3 S344 S350.
49. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001 120 (7 1828 1853.
50. Vidalain PO, Azocar O, Yagita H, Rabourdin-Combe C, Servet-Delprat C. Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand. J Immunol 2001 167 (7 3765 3772.
51. Keeffe EB, Iwarson S, McMahon BJ et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998 27 (3 881 886.
52. Wiedmann M, Liebert UG, Oesen U et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000 31 (1 230 234.
53. Csepregi A, Nemesanszky E, Luettig B, Obermayer-Straub P, Manns MP. LKM3 autoantibodies in hepatitis C cirrhosis: a further phenomenon of the HCV-induced autoimmunity. Am J Gastroenterol 2001 96 (3 910 911.
54. Obermayer-Straub P, Manns MP. Hepatitis C and D, retroviruses and autoimmune manifestations. J Autoimmun 2001 16 (3 275 285.
55. Wesche B, Jaeckel E, Trautwein C et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001 48 (3 378 383.
56. Chan CW, Crafton E, Fan HN et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006 12 (2 207 213.